Somavaratan
(Somapacitan)Phase 3Small molecule
Novo NordiskSomapacitan is used to treat growth hormone deficiency in children and adults. It helps people who don't produce enough growth hormone naturally to grow and develop normally.[1] Somavaratan is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]
Somavaratan is one of 85 small molecule programs targeting Growth. It is currently in Phase 3.
4
Indications
20
Total Trials
7
Active Trials
84
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
79 competitors in Growth
#DrugCompanyPhaseTrials
1Growth Hormone
PfizerPhase 3
Somavaratan
Novo NordiskPhase 3
Neo-Synephrine
EExela Pharma Sciences, LLC.
Phase 3
Recombinant Human Growth Hormone
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Piqray
NovartisPhase 2
Acipimox
Boehringer IngelheimPhase 2
Lenvima
EisaiPreclinical
Zolymbus
AbbViePreclinical
Aricept
EisaiPreclinical
Zyloprim
Jazz PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Growth Hormone Deficiency9 trials
Show 6 more trials
Treatment2 trials
Children1 trial
Hepatic Impairment1 trial
Impaired Renal Function1 trial
6 more indications
Absorption1 trial
Skin1 trial
Born Small for Gestational Age1 trial
SGA1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Somapacitan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Growth Hormone Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company